Cfo Thought Leader

CFOTL: Help us to understand what sets Sage and its offerings apart? Iguchi: In eight years we’ve developed a company that’s at about nine and a half billion dollars in market cap. We are really well positioned from a cash perspective, and we’ve grown to over 650 people strong. Let me tell you a little bit about the history here. We are focused on developing innovative medicines for brain disorders. When we started the company eight years ago, there was a total innovation void. Companies had had many, many failures, and they were shedding their CNS pipelines. Everyone was saying that brain disorders were too tough to tackle, and we said that they were way too important not to. So we were going to take some risks, and we knew that we were going to have to shift the paradigm. That was what we focused on. How do we learn from those mistakes? From the science side, I think that a couple of things that we did really differently was that we always followed the science. We didn’t go after an indication because it lo